Journal
INVESTIGATIONAL NEW DRUGS
Volume 36, Issue 1, Pages 144-146Publisher
SPRINGER
DOI: 10.1007/s10637-017-0484-6
Keywords
Nivolumab; Cholangitis; Non-small cell lung cancer; Immunotherapy
Categories
Ask authors/readers for more resources
Anti-programmed cell death-1 (PD-1) monoclonal antibodies, such as nivolumab, used for the treatment of several tumors, can trigger effector T-cells against tumor- and self-antigens, leading to the occurrence of different immune-related adverse events. Among them, liver injuries are rare and usually transient. To date, only four cases of immune-related cholangitis in non-small cell lung cancer (NSCLC) patients have been described during nivolumab treatment. Here, we describe laboratory tests, imaging and liver biopsy features that confirm this diagnosis as opposed to other forms of autoimmune liver disease; nevertheless, we also provide evidence of the presence of different clinical-pathological patterns of immune-related cholangitis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available